128 related articles for article (PubMed ID: 23642225)
1. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract][Full Text] [Related]
2. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
4. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
5. A patent review of RAF kinase inhibitors (2010-2018).
Man RJ; Zhang YL; Jiang AQ; Zhu HL
Expert Opin Ther Pat; 2019 Sep; 29(9):675-688. PubMed ID: 31370713
[No Abstract] [Full Text] [Related]
6. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
7. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
9. Emerging Raf inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
[TBL] [Abstract][Full Text] [Related]
10. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
Kim DH; Sim T
Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
[TBL] [Abstract][Full Text] [Related]
11. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
13. Regulation of c-Raf-1: therapeutic implications.
Beeram M; Patnaik A; Rowinsky EK
Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J; Shen Q; Labow M; Gaither LA
Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
[TBL] [Abstract][Full Text] [Related]
16. RAF signaling in neuroendocrine neoplasms: from bench to bedside.
Fazio N; Abdel-Rahman O; Spada F; Galdy S; De Dosso S; Capdevila J; Scarpa A
Cancer Treat Rev; 2014 Sep; 40(8):974-9. PubMed ID: 24998490
[TBL] [Abstract][Full Text] [Related]
17. New perspectives for targeting RAF kinase in human cancer.
Karoulia Z; Gavathiotis E; Poulikakos PI
Nat Rev Cancer; 2017 Nov; 17(11):676-691. PubMed ID: 28984291
[TBL] [Abstract][Full Text] [Related]
18. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
19. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I; Shanahan F; Lee J; Hong YS; Shin SJ; Moore AR; Sudhamsu J; Chang MT; Bae I; Dela Cruz D; Hunsaker T; Klijn C; Liau NPD; Lin E; Martin SE; Modrusan Z; Piskol R; Segal E; Venkatanarayan A; Ye X; Yin J; Zhang L; Kim JS; Lim HS; Kim KP; Kim YJ; Han HS; Lee SJ; Kim ST; Jung M; Hong YH; Noh YS; Choi M; Han O; Nowicka M; Srinivasan S; Yan Y; Kim TW; Malek S
Nature; 2021 Jun; 594(7863):418-423. PubMed ID: 33953400
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment.
Jabbarzadeh Kaboli P; Ismail P; Ling KH
PLoS One; 2018; 13(3):e0193941. PubMed ID: 29565994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]